General Oncology, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-23.
General Oncology, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 23, 2026. The filing reports $4.81M sold. Its industry group is Pharmaceuticals. It names Jeffrey Glazier (Executive Officer, Director), Arnold Glazier (Executive Officer, Director), Abid Ansari (Executive Officer) (SEC Form D, April 23, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like General Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-04-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns General Oncology, Inc.
Free to see. No signup.
More on the people and the money behind General Oncology, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in Massachusetts, filed within 90 days of this one, largest first.
Get an email when General Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when General Oncology, Inc. raises, hires or launches. No email unless you switch it on.
Watch General Oncology, Inc. →Get the full cited report on General Oncology, Inc.
What the filing shows about General Oncology, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on General Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives General Oncology, Inc.'s address as 57 Chapel Street, Third Floor, Newton, MA 02458.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for General Oncology, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
General Oncology, Inc. is a registered filer with the SEC (CIK 1658021) and has filed since 2026-04-23. 1 filing is on record, the latest on 2026-04-23.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
General Oncology, Inc.'s Form D of 2026-04-23 names Jeffrey Glazier, Arnold Glazier, Abid Ansari and 2 more as its officers, directors or promoters.
Its new offerings report $4.81M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $4.81M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees or to related entities to those listed in Item 3.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200, after redirecting from https://generaloncology.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Jeffrey Glazier is named as Executive Officer and Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Arnold Glazier is named as Executive Officer and Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Abid Ansari is named as Executive Officer on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Michael Petit is named as Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
Barry Seeman is named as Director on the Form D that General Oncology, Inc. filed with the SEC on 23 April 2026, one of 5 people that filing names.
5 people named on the filing — 3 holding an executive role and 2 as directors only.
Named as of the 2026-04-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about General Oncology, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on General Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on General Oncology, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist General Oncology, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind General Oncology, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (generaloncology.com).
Each opens in a new tab, filled in for General Oncology, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/general-oncology-inc-form-d-26000001